<DOC>
	<DOC>NCT01043146</DOC>
	<brief_summary>Primary Trial objectives: To evaluate the pharmacokinetics and -dynamics of five strengths of COR-1 (10, 40, 80, 160, 240 mg) in 50 healthy, male volunteers after single intravenous administration (8 subjects on verum per dose level, 10 subjects receiving placebo) Secondary objectives: To evaluate safety and tolerability by using adverse events (AEs) and vital signs</brief_summary>
	<brief_title>Safety, Pharmacokinetic and Pharmacodynamic Study of COR-1, an Anti-ß1 Receptor Antibody Cyclopeptide</brief_title>
	<detailed_description>Primary Trial objective: To evaluate the pharmacokinetics and -dynamics of five strengths of COR-1 (10, 40, 80, 160, 240 mg) in healthy, male volunteers after single intravenous administration Secondary objectives: To evaluate safety and tolerability by using adverse events (AEs), vital signs including blood pressure/pulse rate (BP/PR), electrocardiographic examinations (12 lead ECG), evaluation of antibody titer and safety laboratory tests (biochemistry, hematology, coagulation, urinalysis) Methodology: Mono-center, single-blind, dose escalating study with five dose levels (8 subjects on verum per dose level, 2 subjects receiving placebo) in a total of 50 volunteers.</detailed_description>
	<mesh_term>Heart Failure</mesh_term>
	<mesh_term>Antibodies</mesh_term>
	<criteria>Healthy, male Caucasians between 18 and 45 years of age, inclusive Normotensive subjects (systolic BP &lt;140 mmHg and diastolic BP &lt;90 mmHg) Body mass index (BMI) 1927, minimal weight 60 kg Negative results in HIV antibody, HBs antigen (HBsAg) and HCV tests, and negative result in antiß1receptorautoantibody screening Signed Informed Consent Form Normal or clinically irrelevant laboratory findings Autoimmune disorders Kidney diseases Liver diseases, liver function impairments</criteria>
	<gender>Male</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>45 Years</maximum_age>
	<verification_date>March 2013</verification_date>
	<keyword>anti-beta1 adrenergic receptor</keyword>
	<keyword>autoantibody</keyword>
	<keyword>cyclic peptide</keyword>
	<keyword>heart failure</keyword>
</DOC>